Inherited kidney disorder
MONDO:0100191A heterogeneous group of genetic conditions, with Mendelian (autosomal dominant, recessive, or X-linked) or chromosomal etiology that are characterized by abnormalities in the kidney or urinary system.
Also known as: genetic renal disease, inherited kidney disease, inherited renal disorder, nephrogenetic disorder
291 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for kidney disease: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety of a drug called iptacopan for adults with a kidney disease called primary IgA nephropathy. Participants have already completed earlier studies and will continue taking the drug to monitor side effects and see if it helps slow kidney damag…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental cocktail aims to silence Life-Threatening food allergies
Disease control OngoingThis early-stage study tests two drugs together—linvoseltamab and dupilumab—in just 6 adults with severe food allergies. The goal is to see if the combination is safe and can lower IgE antibodies that trigger allergic reactions. Participants must have a history of anaphylaxis to …
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for transplant patients: drug targets kidney protein leak
Disease control OngoingThis study tests a drug called sparsentan for people who have protein in their urine after a kidney transplant due to IgA nephropathy or FSGS. About 20 adults will take the drug once daily for 36 weeks to see if it safely reduces protein levels and protects kidney function. The g…
Phase: PHASE4 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests ravulizumab, a drug that blocks part of the immune system, against a placebo in 579 adults with IgA nephropathy—a kidney disease that can lead to kidney failure. The goal is to see if ravulizumab reduces protein in the urine and preserves kidney function …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Atacicept's Long-Term promise for kidney disease
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effects of atacicept in people with IgA nephropathy, a kidney disease. Participants have already completed a previous trial with atacicept. Researchers will monitor side effects and measure kidney function over time to see if the drug …
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
CAR-T therapy aimed at tough kidney disease in kids — but trial never started
Disease control TerminatedThis was a planned early-stage trial to test whether anti-CD19 CAR-T cells could safely help children with multi-drug resistant nephrotic syndrome, a serious kidney condition. The study was withdrawn before any patients were enrolled, so no data on safety or effectiveness were co…
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to slow kidney failure in common kidney disease
Disease control OngoingThis phase 3 trial tests whether the drug atrasentan can slow kidney function loss in people with IgA nephropathy, a disease that can lead to kidney failure. About 404 participants receive either atrasentan or a placebo, along with standard care. The main goal is to see if atrase…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot could shrink enlarged livers and ease pain
Disease control OngoingThis study tests a drug called CAM2029 (octreotide) given as a weekly or every-other-week shot to people with symptomatic polycystic liver disease. The goal is to see if it can shrink the liver and reduce symptoms like belly pain, bloating, and nausea. About 71 adults with an enl…
Phase: PHASE2, PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to plug kidney leaks in multiple diseases
Disease control OngoingThis phase 2 study tests the drug atrasentan in 103 adults with various kidney diseases that cause protein leakage, including IgA nephropathy and FSGS. Participants take a daily tablet to see if it reduces protein in urine, a sign of kidney damage. The goal is to find a new way t…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests whether the drug povetacicept can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a kidney disease. About 605 participants will receive either the drug or a placebo by injection. The study is active but not recruit…
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug shows promise for slowing kidney disease in IgA nephropathy patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called sibeprenlimab for people with IgA nephropathy, a kidney disease. About 600 adults who completed earlier trials of this drug will continue receiving it for up to 2 more years. Researchers will track side effects and measure…
Phase: PHASE2, PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could zapping kidney nerves tame tough blood pressure in polycystic kidney disease?
Disease control OngoingThis study tests a device that uses ultrasound to burn nerves around the kidney arteries, aiming to lower blood pressure in people with autosomal dominant polycystic kidney disease (ADPKD) whose blood pressure remains high despite medication. 44 participants will be randomly assi…
Phase: NA • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a diabetes pill slow kidney cyst growth? new study tests safety
Disease control OngoingThis study tests whether empagliflozin, a drug used for diabetes, is safe and tolerable for people with autosomal dominant polycystic kidney disease (ADPKD). About 50 adults with moderate kidney function will receive either the drug or a placebo for 12 months. Researchers will mo…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Old asthma drug shows promise for rare genetic disorder
Disease control OngoingThis phase 2 trial tests whether theophylline, a drug used for asthma, can help people with pseudohypoparathyroidism lose weight and improve blood sugar control. The study includes 29 obese participants aged 13 and older. Researchers will measure changes in body mass index and gl…
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a common asthma drug help treat a rare genetic disorder?
Disease control ENROLLING_BY_INVITATIONThis study tests whether theophylline, a drug used for asthma, can help children and young adults with pseudohypoparathyroidism—a rare genetic condition causing early obesity, hormone problems, and short stature. Researchers will check for weight loss, better blood sugar control,…
Phase: PHASE2 • Sponsor: Jaclyn Tamaroff • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Old asthma drug could help kids with rare bone and hormone disorder
Disease control OngoingThis phase 2 trial tests theophylline, a drug used for asthma, in 34 children aged 2 to 12 with pseudohypoparathyroidism, a genetic condition causing obesity, short stature, and hormone resistance. The study aims to see if theophylline can help with weight loss, slow bone growth …
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingThis Phase 3 trial tests sparsentan, a new drug, against irbesartan (a standard treatment) in 406 adults with IgA nephropathy, a kidney disease. The goal is to see if sparsentan better protects kidney function over about 2 years. Participants must have significant protein in thei…
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New pill shows promise for rare kidney cancer in VHL patients
Disease control OngoingThis phase 2 trial is testing a daily pill called belzutifan in 50 people with VHL disease who have kidney cancer. The goal is to see if the drug can shrink tumors. Researchers are also monitoring how long any tumor shrinkage lasts and checking for side effects.
Phase: PHASE2 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New monthly shot could tame rare kidney disease
Disease control OngoingThis study tests a drug called atacicept given once a month to people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if monthly dosing lowers harmful antibodies and reduces protein in the urine, which are signs of kidney damage. About 9…
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New shot shows promise in slowing kidney disease
Disease control OngoingThis phase 3 study tests BION-1301 (Zigakibart) in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants receive either the drug or a placebo as a shot every 2 weeks for 2 years. The main goal is to see if the drug helps preserve kidney f…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a common supplement shield dialysis Kids' hearts?
Disease control ENROLLING_BY_INVITATIONThis study tests whether a daily dose of alpha lipoic acid, an antioxidant supplement, can lower the risk of heart problems in 50 children who are on regular hemodialysis. Participants will either take the supplement or a placebo pill for a period, and researchers will monitor fo…
Phase: PHASE3 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Cystinuria drug trial pulled before it even started
Disease control TerminatedThis study was designed to test whether ADV7103, a combination of potassium citrate and potassium bicarbonate, could help people with cystinuria by making their urine less acidic. The goal was to see if it could raise urine pH to 7.0 or higher, which might reduce kidney stone for…
Phase: PHASE2, PHASE3 • Sponsor: Advicenne Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Kidney drug trial for newborns halted before it began
Disease control TerminatedThis study aimed to see if the drug tolvaptan could help infants with a severe form of polycystic kidney disease (ARPKD) avoid needing dialysis or a kidney transplant in their first year of life. The trial was planned for babies between 28 days and 12 weeks old, but it was withdr…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug could slow kidney failure in IgA nephropathy patients
Disease control OngoingThis study tests a drug called telitacicept in 318 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants are at high risk of worsening despite standard blood pressure medications. The goal is to see if telitacicept can reduce protein in the u…
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Dialysis patients may get to eat fruits again: new diet focuses on hidden potassium
Disease control OngoingThis pilot study tests a new diet for people on hemodialysis who have high potassium levels. Instead of cutting out all high-potassium foods like fruits and vegetables, the diet focuses on avoiding foods with potassium that is easily absorbed, such as additives, processed meats, …
Phase: NA • Sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Diabetes drug repurposed to fight polycystic kidney disease
Disease control OngoingThis phase 4 trial tests whether empagliflozin, a diabetes drug, can safely slow kidney growth and preserve kidney function in 44 adults with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Participants take either empagliflozin or a placebo for 18 month…
Phase: PHASE4 • Sponsor: Hannover Medical School • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug shows promise for tough kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could a diabetes drug shield Kids' kidneys?
Disease control OngoingThis study tests whether dapagliflozin, a drug used in adults for diabetes and kidney protection, can reduce protein leakage in the urine of children with chronic kidney disease. Ten children aged 4 to 18 with persistent proteinuria despite standard therapy will take the drug, an…
Phase: NA • Sponsor: Al-Quds University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug shows promise for slowing kidney disease in IgA nephropathy
Disease control OngoingThis phase 3 trial tests atacicept, a weekly injection, in 376 adults with IgA nephropathy (Berger's disease). The goal is to reduce protein in the urine and slow the loss of kidney function. Participants receive either atacicept or a placebo for about a year. The study is active…
Phase: PHASE3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New DNA reader cracks tough genetic mysteries
Diagnosis OngoingThis study tests a new DNA-reading technology called ultra-long read sequencing to find hidden genetic changes that standard tests miss. Researchers will analyze blood samples from 15 patients with known or suspected genetic variants in difficult-to-read DNA regions. The goal is …
Phase: NA • Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
Could a simple supplement shield bones and kidneys from common heartburn drugs?
Prevention TerminatedThis trial investigates whether a daily effervescent supplement containing calcium, magnesium, and citrate can prevent bone loss, magnesium deficiency, and kidney damage in adults who take proton pump inhibitors (PPIs) long-term for conditions like heartburn or GERD. Participants…
Phase: PHASE3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Magnesium-Rich diet may prevent chemo side effect in ovarian cancer
Prevention OngoingThis study looks at whether eating a diet high in magnesium can help prevent low blood magnesium levels in women with ovarian cancer who are receiving carboplatin chemotherapy. Low magnesium is a common side effect of this treatment. The study enrolled 26 participants and will me…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 09:06 UTC
-
Ground-Level vision test could help retinitis pigmentosa patients walk better
Knowledge-focused TerminatedThis study was designed to see if a new method of measuring the visual field—by projecting vision zones on the ground—helps people with retinitis pigmentosa understand their remaining sight and improve their walking rehabilitation. The trial was withdrawn before enrolling any par…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Long-Term study sheds light on rare bone and hormone disorder
Knowledge-focused OngoingThis study follows 600 people with Albright hereditary osteodystrophy, a rare genetic condition affecting bones and hormones. Researchers are looking at how growth hormone treatment affects height and weight in those with a related hormone problem, and also studying thinking and …
Phase: NA • Sponsor: Connecticut Children's Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Can shedding pounds protect kidneys? new study investigates
Knowledge-focused OngoingThis study looks at whether losing weight over two years can improve how the kidneys use oxygen and how the body responds to insulin in people with autosomal dominant polycystic kidney disease (ADPKD) who are overweight. Researchers will use PET scans and insulin tests to measure…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Gene study aims to unlock secrets of kidney disease
Knowledge-focused OngoingThis study looks at 401 people with autosomal dominant polycystic kidney disease (ADPKD) to see how different versions of the PKD1 gene relate to patient traits like age at diagnosis and body size. Researchers are not testing any treatment—they are simply gathering information to…
Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study links blood markers to kidney disease progression in ADPKD
Knowledge-focused OngoingThis study looks at how certain blood chemicals and blood vessel function relate to kidney disease severity in people with early-stage Autosomal Dominant Polycystic Kidney Disease (ADPKD). Researchers will measure homocysteine levels and blood vessel health in 80 participants age…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Obesity's hidden role in kidney stones revealed?
Knowledge-focused OngoingThis study looks at how obesity changes the way the body handles oxalate, a substance that can form kidney stones. Researchers will give 22 calcium oxalate stone formers a controlled low-oxalate diet and a special tracer to measure oxalate absorption, kidney handling, and natural…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can your genes predict kidney stones? mayo clinic launches huge study
Knowledge-focused ENROLLING_BY_INVITATIONThis study from Mayo Clinic looks at whether certain gene variants make people more likely to form calcium oxalate kidney stones. Researchers will compare 2,900 adults with and without a history of kidney stones, analyzing blood samples and lifestyle factors. The goal is to bette…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Scientists hunt for hidden mutations behind polycystic kidney disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects kidney tissue from 100 adults with autosomal dominant polycystic kidney disease (ADPKD) who are already scheduled for kidney removal. Researchers will analyze the tissue for additional genetic mutations that may drive cyst formation. The goal is to better unde…
Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Robotic surgery may speed recovery for polycystic kidney patients
Knowledge-focused OngoingThis study looks at whether using a robot to remove one kidney in people with autosomal dominant polycystic kidney disease (ADPKD) is safe and effective compared to traditional open surgery. Researchers will track 57 adult patients to see if the robotic approach leads to fewer co…
Sponsor: University of Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
New ultrasound technique could spot kidney damage earlier in ADPKD
Knowledge-focused OngoingThis study is testing a new type of ultrasound called super-resolution ultrasound (SRU) to get a detailed look at the tiny blood vessels in the kidneys. Researchers will compare images from 34 people with ADPKD and healthy volunteers to see if SRU can detect differences in blood …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Can simple blood tests predict kidney decline in ADPKD?
Knowledge-focused OngoingThis study from Mayo Clinic is looking at 100 people with autosomal dominant polycystic kidney disease (ADPKD) to see if certain markers in the blood and urine can predict how fast their kidney disease gets worse. Researchers will measure kidney size and function over time and co…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Tiny organisms may hold clues to kidney disease
Knowledge-focused TerminatedThis study aims to identify the bacteria and fungi living in the urinary tract of people with calcium oxalate kidney stones or kidney cancer. Researchers will compare these microbial communities to those in healthy volunteers. The goal is to better understand how these tiny organ…
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:24 UTC
-
Can kidney size predict disease progression in ADPKD? new study investigates
Knowledge-focused OngoingThis observational study reviews medical records from 70 adults with advanced autosomal dominant polycystic kidney disease (ADPKD) who are already taking the drug octreotide LAR. Researchers want to see if baseline kidney volume and other factors can predict how quickly kidney fu…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:19 UTC
-
300 volunteers help create medical image bank for science
Knowledge-focused OngoingThis study gathers MRI, CT, and ultrasound images from 300 adults—some healthy, some with kidney or brain disease—to build a collection for future not-for-profit research. No new treatments are being tested; the goal is to make medical images available to scientists for advancing…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:28 UTC
-
Massive study seeks genetic clues to protect black HIV patients from organ damage
Knowledge-focused OngoingThis study follows over 3,000 Black people with HIV in the UK to understand how genes and lifestyle affect their risk for kidney disease, heart disease, diabetes, and obesity. Researchers collect health data and blood/urine samples to find genetic markers that predict these condi…
Sponsor: King's College Hospital NHS Trust • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:23 UTC
-
Fake data, real hope: AI could speed up rare disease trials
Knowledge-focused OngoingThis study looks at whether artificial intelligence can create realistic, privacy-safe copies of health records from people with a rare kidney disease called ADPKD. Researchers will use these simulated datasets to run virtual clinical trials and see if they produce similar result…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:51 UTC